272 related articles for article (PubMed ID: 32108577)
1. [Theophylline adenosine dipyridamole (CTAD) and citrate evaluation to survey unfractionated heparin treatment: a delayed centrifugation validation for anti-Xa measurement?].
Billoir P; Clavier T; Guilbert A; Barbay V; Chrétien MH; Fresel M; Abriou C; Girault C; Le Cam Duchez V
Ann Biol Clin (Paris); 2020 Feb; 78(1):27-34. PubMed ID: 32108577
[TBL] [Abstract][Full Text] [Related]
2. Is citrate theophylline adenosine dipyridamole (CTAD) better than citrate to survey unfractionated heparin treatment? Has delayed centrifugation a real impact on this survey?
Billoir P; Clavier T; Guilbert A; Barbay V; Chrétien MH; Fresel M; Abriou C; Girault C; Le Cam Duchez V
J Thromb Thrombolysis; 2019 Aug; 48(2):277-283. PubMed ID: 31098816
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of CTAD (citrate-theophylline-adenosine-dipyridamole) as a universal anticoagulant in dogs.
Granat FA; Geffré A; Lucarelli LA; Braun JD; Trumel C; Bourgès-Abella NH
J Vet Diagn Invest; 2017 Sep; 29(5):676-682. PubMed ID: 28673194
[TBL] [Abstract][Full Text] [Related]
4. The PiCT
Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
[TBL] [Abstract][Full Text] [Related]
5. Monitoring heparin therapy by the activated partial thromboplastin time--the effect of pre-analytical conditions.
van den Besselaar AM; Meeuwisse-Braun J; Jansen-Grüter R; Bertina RM
Thromb Haemost; 1987 Apr; 57(2):226-31. PubMed ID: 3603414
[TBL] [Abstract][Full Text] [Related]
6. Monitoring heparin therapy: stability of two different anti-Xa assays using blood samples collected in citrate-containing and CTAD tubes.
Gremillet M; Talon L; Lebreton A; Sinegre T
Thromb J; 2023 Feb; 21(1):21. PubMed ID: 36803983
[TBL] [Abstract][Full Text] [Related]
7. Comparison of different anticoagulant associations on haemostasis and biochemical analyses in feline blood specimens.
Granat F; Monzali C; Jeunesse E; Guerlin M; Trumel C; Geffré A; Bourgès-Abella N
J Feline Med Surg; 2017 Apr; 19(4):394-402. PubMed ID: 26887655
[TBL] [Abstract][Full Text] [Related]
8. Monitoring unfractionated heparin therapy. 4 hour-stability of anti-Xa activity in unspun citrated tubes.
Toulon P; Appert-Flory A; Fischer F; Buvat S; Jambou D; Mahagne MH
Thromb Res; 2020 Feb; 186():7-12. PubMed ID: 31837560
[TBL] [Abstract][Full Text] [Related]
9. A low volume specimen container suitable for monitoring the aPTT of heparinized patients.
Ray MJ; Carroll PA; Just SJ; Hawson GA
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):805-7. PubMed ID: 8292732
[TBL] [Abstract][Full Text] [Related]
10. Monitoring treatments with unfractionated heparin: CTAD must be used instead of citrate as the anticoagulant solution when using partial-draw collection tubes. Results of a multicenter evaluation.
Toulon P; Abecassis L; Smahi M; Ternisien C
Thromb Res; 2010 Dec; 126(6):536-42. PubMed ID: 20950840
[TBL] [Abstract][Full Text] [Related]
11. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
Vandiver JW; Vondracek TG
Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
[TBL] [Abstract][Full Text] [Related]
12. Factors Influencing Anti-Xa Assays: A Multicenter Prospective Study in Critically Ill and Noncritically Ill Patients Receiving Unfractionated Heparin.
Lasne D; Toussaint-Hacquard M; Delassasseigne C; Bauters A; Flaujac C; Savard P; Mouton C; De Maistre E; Stepanian A; Eschwège V; Delrue M; Georges JL; Gros A; Mansour A; Leroy G; Jouffroy R; Mattei M; Beurton A; Pontis A; Neuwirth M; Nedelec-Gac F; Lecompte T; Curis E; Siguret V; Gouin-Thibault I
Thromb Haemost; 2023 Dec; 123(12):1105-1115. PubMed ID: 37321244
[TBL] [Abstract][Full Text] [Related]
13. Underestimation of unfractionated heparin therapy assessment due to platelet activation when using partial-draw (pediatric) citrate collection tubes.
Desconclois C; Eschwège V; Proulle V; Boutekedjiret T; Dreyfus M; Toulon P
Thromb Res; 2014 Nov; 134(5):1117-22. PubMed ID: 25248688
[TBL] [Abstract][Full Text] [Related]
14. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin.
Belk KW; Laposata M; Craver C
J Thromb Haemost; 2016 Nov; 14(11):2148-2157. PubMed ID: 27543785
[TBL] [Abstract][Full Text] [Related]
15. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulation Monitoring with Activated Partial ThromboPlastin Time and Anti-Xa Activity in Intensive Care Unit Patients: Interest of Thrombin Generation Assay.
Billoir P; Elie T; Levy JH; Besnier E; Dureuil B; Veber B; Le Cam-Duchez V; Clavier T
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232517
[TBL] [Abstract][Full Text] [Related]
17. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
[TBL] [Abstract][Full Text] [Related]
18. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.
Takemoto CM; Streiff MB; Shermock KM; Kraus PS; Chen J; Jani J; Kickler T
Am J Clin Pathol; 2013 Apr; 139(4):450-6. PubMed ID: 23525615
[TBL] [Abstract][Full Text] [Related]
19. Anti-Factor Xa-Based Monitoring of Unfractionated Heparin: Clinical Outcomes in a Pediatric Cohort.
Saini S; Folta AN; Harsh KL; Stanek JR; Dunn AL; O'Brien SH; Kumar R
J Pediatr; 2019 Jun; 209():212-219.e1. PubMed ID: 30961988
[TBL] [Abstract][Full Text] [Related]
20. Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator.
Al-Jazairi A; Raslan S; Al-Mehizia R; Dalaty HA; De Vol EB; Saad E; Alanazi M; Owaidah T
Ann Pharmacother; 2021 May; 55(5):592-604. PubMed ID: 32959678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
